Trials / Completed
CompletedNCT00745576
Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered
An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-administered Orally to Healthy Young Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effects of multiple doses of verapamil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of co-administration of SAM-531 and verapamil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAM-531 |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-09-03
- Last updated
- 2010-02-08
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00745576. Inclusion in this directory is not an endorsement.